Category: Edwards LifesciencesSyndicate content

Edwards Lifesciences posts double-digit Q3 sales, earnings increases

October 23, 2014 by Brad Perriello

Edwards Lifesciences reports 3rd-quarter sales and earnings growth in excess of 20% and raises its outlook for the rest of the year.

Edwards Lifesciences posts double-digit Q3 sales, earnings increases

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Mazzo suspended at Versant Ventures after insider trading indictment | Personnel Moves

October 15, 2014 by Brad Perriello

James Mazzo and Versant Ventures agree to suspend Mazzo after his indictment on insider trading charges stemming from Abbott's $2.8 billion acquisition of Advanced Medical Optics.

Mazzo suspended at Versant Ventures after insider trading indictment | Personnel Moves

Versant Ventures and James Mazzo agreed that Mazzo will "suspend any activities" at the venture capital shop following his indictment last month on insider trading charges.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Edwards Lifesciences is back in Wall Street's good graces | Medtech Wall Street news for the week of October 6, 2014

October 9, 2014 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: Wall Street loves Edwards Lifesciences again; Becton Dickinson to buy CareFusion for $12 billion in cash, stock; Proxy war rages on at Echo Therapeutics; Platinum fires back at Echo Therapeutics over 'rogue' directors; Echo Therapeutics hits back at Platinum Equity

Wall Street loves Edwards Lifesciences again

October 3, 2014 by Brian Johnson

Edwards: Medtronic TAVI settlement boosts bottom line in Q2

Allergan CEO Pyott steps down from Edwards Lifesciences board | Personnel Moves

October 7, 2014 by Brad Perriello

Allergan CEO David Pyott steps down from the board at Edwards Lifesciences to devote more time to his chief executive duties.

Allergan CEO Pyott steps down from Edwards Lifesciences board | Personnel Moves

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Wall Street loves Edwards Lifesciences again

October 3, 2014 by Brian Johnson

Edwards Lifesciences is flirting with all time highs on The Street after nearly 2 years of bearish results.

Edwards: Medtronic TAVI settlement boosts bottom line in Q2

Edwards Lifesciences (NYSE:EW) is back in Wall Street's good graces, with shares of the Irvine, Calif.-based heart valve maker approaching all time highs after nearly 2 years of down performance.

Analyst: Edwards Lifesciences' Sapien 3 poised to lead TAVI market | MassDevice.com On Call

October 2, 2014 by Brad Perriello

The Sapien 3 replacement heart valve made by Edwards Lifesciences is poised to take the lead in the market for transcatheter aortic valve implants, according to one analyst.

MassDevice.com On Call

MASSDEVICE ON CALL — Edwards Lifesciences (NYSE:EW) is poised to take the lead in the transcatheter aortic valve market with its Sapient 3 replacement heart valve, according to Leerink Partners analyst Danielle Antalffy.

Replace aortic valve in a timely fashion: researchers

September 26, 2014 by MassDevice

Researchers recommend quick surgery for patients with severe symptomatic aortic stenosis

Replace aortic valve in a timely fashion: researchers

NEW YORK (Reuters Health) - Patients with severe symptomatic aortic stenosis who need aortic valve replacement should have the surgery as soon as possible, new research suggests.

"Our research highlights the importance of treating aortic stenosis in a timely fashion. Delays lead to unnecessary risk and patients should ideally have an aortic valve replacement within a month of diagnosis," Dr. Chris Malaisrie of Northwestern University, Feinberg School of Medicine, in Chicago, Illinois, told Reuters Health by email.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp